Related Experiment Videos
Chemokines in islet allograft rejection
Reza Abdi1, Terry K Means, Andrew D Luster
1Laboratory of Immunogenetics and Transplantation, Renal Division, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA. rabdi@rics.bwh.harvard.edu
Diabetes/Metabolism Research and Reviews
|June 6, 2003
Summary
Targeting chemokine receptor CCR5 significantly prolonged islet allograft survival by shifting the immune response. This highlights organ-specific chemokine roles in acute rejection and potential therapeutic strategies.
Area of Science:
- Immunology
- Transplantation Biology
- Molecular Medicine
Background:
- Chemokines regulate leukocyte behavior and are implicated in allograft rejection.
- CXCR3 is more critical in cardiac than CCR2/CCR5 in cardiac allograft rejection.
- Chemokine receptor systems' roles vary across different allograft types.
Purpose of the Study:
- To investigate the role of chemokine receptors CCR2, CCR5, and CXCR3 in islet allograft rejection.
- To determine the impact of targeting specific chemokine receptors on allograft survival.
- To understand the immune response modulation following chemokine receptor blockade.
Main Methods:
- Analysis of chemokine receptor and ligand expression in rejecting islet allografts.
- Experimental targeting of CCR5 in a preclinical islet transplantation model.
- Assessment of immune cell profiles (Th1/Th2) and allograft survival rates.
Main Results:
- CCR2, CCR5, CXCR3, and Th1 cytokines were upregulated in rejecting islet allografts.
- Blocking CCR5 significantly extended islet allograft survival.
- CCR5 blockade induced a shift towards a Th2 immune response.
Conclusions:
- Chemokine expression and function are organ-specific during acute rejection.
- Targeting CCR5 offers a promising strategy to prevent islet allograft rejection.
- Modulating chemokine pathways can alter the immune response to promote graft survival.